53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer

Rachel M. Hurley, Andrea E. Wahner Hendrickson, Daniel W. Visscher, Peter Ansell, Maria I. Harrell, Jill M. Wagner, Vivian Negron, Krista M. Goergen, Matthew J. Maurer, Ann L. Oberg, X. Wei Meng, Karen S. Flatten, Maja J.A. De Jonge, Carla D. Van Herpen, Jourik A. Gietema, Rutger H.T. Koornstra, Agnes Jager, Martha W. den Hollander, Matthew Dudley, Stacie P. ShepherdElizabeth M. Swisher, Scott H. Kaufmann

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Fingerprint

Dive into the research topics of '53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences